XHANCE is the first and only nasal medication ever shown in Phase 3 controlled trialsto reduce exacerbations for patients with chronic sinusitis Pre-planned analysis of pooled data from the landmark ...

ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical ...

Xhance (fluticasone propionate) is a brand-name nasal spray that’s prescribed for chronic rhinosinusitis with or without nasal polyps in adults. Xhance has interactions with some other drugs, such as ...

YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (OPTN) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today ...

NAVIGATE II: XHANCE produced significant improvement in both co-primary outcome measures, congestion/obstruction at week four and total polyp grade at week 16 EXHANCE-12: Over one year of treatment, ...

YARDLEY, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Optinose (OPTN) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today ...

Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient market Acquisition advances Paratek’s ...

Optinose is conservatively projecting peak sales of $300 million for its drug-device product Xhance, which had sales of about $71 million last year. Bucks County firm wins FDA approval for wider use ...

YARDLEY, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced ...